

# Science

Below is a list of scientific references, concerning addiction and treatments. Some allow access to the entire study some need to be purchased or obtained through a library.

---

## Practical Considerations for the Clinical Use of Buprenorphine

[PDF - 284K]

Hendrée E. Jones, Ph.D.

Ahmadi, J., 2002. A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. *Drug and Alcohol Dependence* 66(2):111-114. [Abstract Available](#)

Amass, L., et al., 1994. Alternate-day dosing during buprenorphine treatment of opiate dependence. *Life Sciences* 54(17):1215-1228. [Abstract Available](#)

Amass, L., et al., 1998. Alternate-day buprenorphine dosing is preferred to daily dosing by opiate-dependent humans. *Psychopharmacology* (Berlin) 136(3):217-225. [Abstract Available](#)

Amass, L.; Kamien, J.B.; and Mikulich, S.K., 2000. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. *Drug and Alcohol Dependence* 58(1-2):143-152. [Abstract Available](#)

Amass, L.; Kamien, J.B.; and Mikulich, S.K., 2001. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. *Drug and Alcohol Dependence* 61(2):173-181. [Abstract Available](#)

Barnett, P.G.; Zaric, G.S.; and Brandeau, M.L., 2001. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. *Addiction* 96(9):1267-1278. [Abstract Available](#)

Berson, A., et al., 2001a. Hepatitis after intravenous buprenorphine misuse in heroin addicts. *Journal of Hepatology* 34(2):346-350. [Abstract Available](#)

Berson, A., et al., 2001b. Mechanisms for experimental buprenorphine hepatotoxicity: Major role of mitochondrial dysfunction versus metabolic activation. *Journal of Hepatology* 34(2):261-269. [Abstract Available](#)

Bertschy, G., et al., 1996. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. *Therapeutic Drug Monitoring* 18:570-572. [Abstract Available](#)

Bickel, W.K., et al., 1999. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. *Psychopharmacology* (Berlin) 146(2):111-118. [Abstract Available](#)

Bouchez, J.; Beauverie, P.; and Touzeau, D., 1998. Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. *European Addiction Research* 4 (Suppl 1):8-12. [Abstract Available](#)

Carrieri, M.P., et al., 2000. Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART. The Manif-2000 Study Group. *Drug and Alcohol Dependence* 60(1):51-54. [Abstract Available](#)

de Castro, J., et al., 1996. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. *Biopharmaceutics Drug and Disposition* 17(7):551-563. [Abstract Available](#)

- Chiang, C.N., and Hawks, R.L., 2003. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. *Drug and Alcohol Dependence* 70(Suppl): S39-S47. [Abstract Available](#)
- Clarke, S., et al., 2002. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. *Clinical Infectious Diseases* 34(8):1143-1145. [Abstract Available](#)
- Comer, S.D., and Collins, E.D., 2002. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. *Journal of Pharmacology and Experimental Therapeutics* 303(2):695-703. [Abstract Available](#)
- Cowan, A.; Lewis, J.W.; and Macfarlane, I.R., 1977. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. *British Journal of Pharmacology* 60(4):537-545. [Abstract Available](#)
- DeMaria, P.A., Jr., and Serota, R.D., 1999. A therapeutic use of the methadone fluvoxamine drug interaction. *Journal of Addictive Disorders* 18:5-12. [Abstract Available](#)
- Eissenberg, T., et al., 1996. Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. *Journal of Pharmacology and Experimental Therapeutics* 276(2):449-459. [Abstract Available](#)
- Ernst, E., et al., 2002. Methadone-related deaths in Western Australia, 1993-1999. *Australian and New Zealand Journal of Public Health* 26:364-370. [Abstract Available](#)
- Fhima, A., et al., 2001. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). *Annales de Médecine Interne (Paris)* 152(Suppl):26-36. [Abstract Available](#)
- Fischer, G., et al., 1999. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. *Addiction* 94(9):1337-1347. [Abstract Available](#)
- Fudala, P.J., and Johnson, R.E., 1995. Clinical efficacy studies of buprenorphine for the treatment of opiate dependence. In: A. Cowan and J.W. Lewis (Eds.), *Buprenorphine: Combatting Drug Abuse With a Unique Opioid*. New York: Wiley-Liss, pp. 213-239.
- Fudala, P.J., et al., 1990. Use of buprenorphine in the treatment of opioid addiction: II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. *Clinical Pharmacology and Therapeutics* 47(4):525-534. [Abstract Available](#)
- Fudala, P.J., et al., 1998. Effects of buprenorphine and naloxone in morphine-stabilized opiate addicts. *Drug and Alcohol Dependence* 50(1):1-8. [Abstract Available](#)
- Fudala, P.J., et al., 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *New England Journal of Medicine* 349 (Sept. 4):949-958. [Abstract Available](#)
- George, T.P., et al., 2000. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. *Biological Psychiatry* 47(12): 1080-1086. [Abstract Available](#)
- Gowing, L.; Ali, R.; and White, J., 2002. Buprenorphine for the management of opioid withdrawal. *Cochrane Database of Systematic Reviews* (2):CD002025. [Abstract Available](#)
- Greenwald, M.K., et al., 2002. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. *Psychopharmacology (Berlin)* 160(4):344-352. [Abstract Available](#)
- Gross, A., et al., 2001. Limits to buprenorphine dosing: A comparison between quintuple and sextuple the maintenance dose every 5 days. *Drug and Alcohol Dependence* 64(1):111-116. [Abstract Available](#)
- Harris, D.S., et al., 2000. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. *Drug and Alcohol Dependence* 61(1):85-94.

[Abstract Available](#)

Heelon, M.W., and Meade, L.B., 1999. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. *Pharmacotherapy* 19(4):471-472. [Abstract Available](#)

Ibrahim, R.B., et al., 2000. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. *Life Sciences* 66(14):1293-1298. [Abstract Available](#)

Iribarne, C., et al., 1998. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. *Drug Metabolism Disposition* 26(3):257-260. [Abstract Available](#)

Jasinski, D.R.; Pevnick, J.S.; and Griffith, J.D., 1978. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. *Archives of General Psychiatry* 35(4):501-516. [Abstract Available](#)

Johnson, R.E.; Jaffe, J.H.; and Fudala, P.J., 1992. A controlled trial of buprenorphine treatment for opioid dependence. *Journal of the American Medical Association* 267(20):2750-2755. [Abstract Available](#)

Johnson, R.E.; Jones, H.E.; and Fischer, G., 2003. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. *Drug and Alcohol Dependence* 70 (2 Suppl.): S87-S101. [Abstract Available](#)

Johnson, R.E.; Strain, E.C.; and Amass, L., 2003. Buprenorphine: How to use it right. *Drug and Alcohol Dependence* 70(2 Suppl.):S59-S77. [Abstract Available](#)

Johnson, R.E., et al., 1989. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. *Clinical Pharmacology and Therapeutics* 46(3):335-343. [Abstract Available](#)

Johnson, R.E., et al., 1995a. A placebo-controlled clinical trial of buprenorphine as a treatment for opioid dependence. *Drug and Alcohol Dependence* 40(1):17-25. [Abstract Available](#)

Johnson, R.E., et al., 1995b. Buprenorphine treatment of opioid dependence: Clinical trial of daily versus alternate-day dosing. *Drug and Alcohol Dependence* 40(1):27-35. [Abstract Available](#)

Johnson, R.E., et al., 2000. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *New England Journal of Medicine* 343(18):290-297. [Abstract Available](#)

Kakko, J., et al., 2003. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized placebocontrolled trial. *Lancet* 361(9358):662-668. [Abstract Available](#)

Kaltenbach, K.; Berghella, V.; and Finnegan, L., 1998. Opioid dependence during pregnancy: Effects and management. *Obstetrics and Gynecology Clinics of North America* 25(1):139-151. [Abstract Available](#)

Kandall, S.R., et al., 1999. The methadone-maintained pregnancy. *Clinics in Perinatology* 26(1):173-183. [Abstract Available](#)

Kilicarslan, T., and Sellers, E.M., 2000. Lack of interaction of buprenorphine with flunitrazepam metabolism. *American Journal of Psychiatry* 157(7):1164-1166. [Abstract Available](#)

Kintz, P., 2002. Buprenorphine-related deaths. In P. Kintz and P. Marquet (Eds.), *Buprenorphine Therapy of Opiate Addiction*. Totowa, NJ: *Humana Press*, pp. 109-118. [Abstract Available](#)

Kosten, T.R., et al., 1990. Opiate antagonist challenges in buprenorphine-maintained patients. *Drug and Alcohol Dependence* 25(1):73-78. [Abstract Available](#)

Kosten, T.R., et al., 1992. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. *Archives of General Psychiatry* 49(11):894-898. [Abstract Available](#)

- Kosten, T.R., et al., 1993. Buprenorphine versus methadone maintenance for opioid dependence. *Journal of Nervous and Mental Disease* 181(6):358-364. [Abstract Available](#)
- Kosten, T.R., et al., 2002. Ketoconazole increases cocaine and opioid use in methadone-maintained patients. *Drug and Alcohol Dependence* 66(2):173-180. [Abstract Available](#)
- Kreek, M.J., 1981. Metabolic interactions between opiates and alcohol. *Annals of the New York Academy of Sciences* 362(1):36-49. [Abstract Available](#)
- Krook, A.L., et al., 2002. A placebo-controlled study of high-dose buprenorphine in opiate-dependents waiting for medication-assisted rehabilitation in Oslo, Norway. *Addiction* 97(5):533-542. [Abstract Available](#)
- Kuhlman, J.J., Jr., et al., 1998. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. *Addiction* 93(4):549-559. [Abstract Available](#)
- Lange, W.R., et al., 1990. Safety and side effects of buprenorphine in the clinical management of heroin addiction. *Drug and Alcohol Dependence* 26(1):19-28. [Abstract Available](#)
- Leshner, A.I., 2003. Accessing opiate dependence treatment medications: Buprenorphine products in an office setting. *Drug and Alcohol Dependence* 70(2 Suppl.):S103-S104. [Abstract Available](#)
- Levin, F.R., et al., 1997. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. *American Journal on Addictions* 6(2):105-116. [Abstract Available](#)
- Lindhardt, K., et al., 2001. Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. *International Journal of Pharmaceutics* 217(1-2):121-126. [Abstract Available](#)
- Ling, W., and Smith, D., 2002. Buprenorphine: Blending practice and research. *Journal of Substance Abuse Treatment* 23(2):87-92. [Abstract Available](#)
- Ling, W., et al., 1996. A controlled trial comparing buprenorphine and methadone maintenance in opiate dependence. *Archives of General Psychiatry* 53(5):401-407. [Abstract Available](#)
- Ling, W., et al., 1998. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. *Addiction* 93(4):475-486. [Abstract Available](#)
- Lintzeris, N., et al., 2002. Training primary health care professionals to provide buprenorphine and LAAM treatment. *Substance Abuse* 23(4):245-254. [Abstract Available](#)
- Lintzeris, N., et al., 2003. Buprenorphine dosing regimen for inpatient heroin withdrawal: A symptom-triggered dose titration study. *Drug and Alcohol Dependence* 70(3):287-294. [Abstract Available](#)
- Martin, W.R., et al., 1976. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. *Journal of Pharmacology and Experimental Therapeutics* 197(3):517-532. [Abstract Available](#)
- Mattick, R.P., et al., 2003. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. *Addiction* 98(4):441-452. [Abstract Available](#)
- McCance-Katz, E.F., et al., 1998. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). *Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology* 18(5):435-443. [Abstract Available](#)
- McCance-Katz, E.F., et al., 2003. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. *Clinical Infectious Diseases* 37(4):476-482. [Abstract Available](#)
- Mello, N.K., and Mendelson, J.H., 1980. Buprenorphine suppresses heroin use by heroin addicts.

*Science* 207(4431):657-659 [Abstract Available](#).

Mendelson, J., and Jones, R.T., 2003. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? *Drug and Alcohol Dependence* 70(2 Suppl.):S29-S37. [Abstract Available](#)

Mendelson, J., et al., 1996. Buprenorphine and naloxone interactions in opiate-dependent volunteers. *Clinical Pharmacology and Therapeutics* 60(1):105-114. [Abstract Available](#)

Mendelson, J., et al., 1997a. Bioavailability of sublingual buprenorphine. *Journal of Clinical Pharmacology* 37(1):31-37. [Abstract Available](#)

Mendelson, J., et al., 1997b. Buprenorphine and naloxone interactions in methadone maintenance patients. *Biological Psychiatry* 41(11):1095-1101. [Abstract Available](#)

Mendelson, J., et al., 1999. Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. *Psychopharmacology* (Berlin) 141(1):37-46. [Abstract Available](#)

O'Brien, C.P., et al., 1978. Clinical pharmacology of narcotic antagonists. *Annals of the New York Academy of Sciences* 311(1):232-239. [Abstract Available](#)

O'Connor, P.G., 2000. Treating opioid dependence—new data and new opportunities. *New England Journal of Medicine* 343(18):1332-1334. [Abstract Available](#)

Oliveto, A., et al., 1995. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. *Journal of Substance Abuse Treatment* 12(6):423-428. [Abstract Available](#)

Paetzold, W., et al., 2000. Detoxification of poly-substance abusers with buprenorphine: Effects on affect, anxiety, and withdrawal symptoms. *Nervenarzt* (Berlin) 71(9):722-729. [Abstract Available](#)

Pani, P.P., et al., 2000. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. *Drug and Alcohol Dependence* 60(1):39-50. [Abstract Available](#)

Perez de los Cobos, J.P., et al., 2000. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. *Drug and Alcohol Dependence* 59(3):223-233. [Abstract Available](#)

Petitjean, S., et al., 2001. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug and Alcohol Dependence* 62(1):97-104. [Abstract Available](#)

Petry, N.M.; Bickel, W.K.; and Badger, G.J., 2000. A comparison of four buprenorphine dosing regimens using open-dosing procedures: Is twice-weekly dosing possible? *Addiction* 95(7):1069-1077. [Abstract Available](#)

Petry, N.M.; Bickel, W.K.; and Badger, G.J., 2001. Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens. *Addiction* 96(6):823-834. [Abstract Available](#)

Petry, N.M., et al., 2000. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. *American Journal on Addictions* 9(3):265-269. [Abstract Available](#)

Pickworth, W.B., et al., 1993. Subjective and physiologic effects of intravenous buprenorphine in humans. *Clinical Pharmacology and Therapeutics* 53(5):570-576. [Abstract Available](#)

Preston, K.L.; Bigelow, G.E.; and Liebson, I.A., 1988. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. *Psychopharmacology* (Berlin) 94(4):484-490. [Abstract Available](#)

Preston, K.L.; Bigelow, G.E.; and Liebson, I.A., 1990. Effects of sublingually given naloxone in opioid-dependent human volunteers. *Drug and Alcohol Dependence* 25(1):27-34. [Abstract Available](#)

Rainey, P.M., et al., 2002. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. *American Journal on Addictions* 11(1):66-74. [Abstract Available](#)

Reynaud, M., et al., 1998. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. *Addiction* 93(9):1385-1392. [Abstract Available](#)

Rosenheck, R., and Kosten, T., 2001. Buprenorphine for opiate addiction: Potential economic impact. *Drug and Alcohol Dependence* 63(3):253-262. [Abstract Available](#)

Rothman, R.B., et al., 2000. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. *Journal of Substance Abuse Treatment* 18(3):277-281. [Abstract Available](#)

Schlatter, J., et al., 1999. Drug interactions with methadone. *Presse Medicale* (Paris) 28(25):1381-1384. [Abstract Available](#)

Schottenfeld, R.S.; Pakes, J.R.; and Kosten, T.R., 1998. Prognostic factors in buprenorphine- versus methadone-maintained patients. *Journal of Nervous and Mental Disease* 186(1):35-43. [Abstract Available](#)

Schottenfeld, R.S., et al., 1997. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. *Archives of General Psychiatry* 54(8):713-720. [Abstract Available](#)

Schottenfeld, R.S., et al., 2000. Thrice-weekly versus daily buprenorphine maintenance. *Biological Psychiatry* 47(12):1072-1079. [Abstract Available](#)

Singh, R.A., et al., 1992. Cases of buprenorphine abuse in India. *Acta Psychiatrica Scandinavica* 86(1):46-48. [Abstract Available](#)

Stevens, R.C., et al., 2003. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. *Journal of Acquired Immune Deficiency Syndrome* 33(5):650-651. [Abstract Available](#)

Stoller, K.B., et al., 2001. Effects of buprenorphine/naloxone in opioid-dependent humans. *Psychopharmacology* (Berlin) 154(3):230-242. [Abstract Available](#)

Strain, E.C. (Ed.), 2001. Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. <http://buprenorphine.samhsa.gov>. January 30, 2003. [Full Text Available \[pdf\]](#)

Strain, E.C., et al., 1992. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. *Journal of Pharmacology and Experimental Therapeutics* 261(3):985-993. [Abstract Available](#)

Strain, E.C., et al., 1993. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. *Journal of Pharmacology and Experimental Therapeutics* 267(2):624-634. [Abstract Available](#)

Strain, E.C., et al., 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *American Journal of Psychiatry* 151(7):1025-1030. [Abstract Available](#)

Strain, E.C., et al., 1995. Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. *Journal of Pharmacology and Experimental Therapeutics* 272(2):628-638. [Abstract Available](#)

Strain, E.C., et al., 1997. The effects of buprenorphine in buprenorphine-maintained volunteers. *Psychopharmacology* (Berlin) 129(4):329-338. [Abstract Available](#)

Strain, E.C., et al., 2000. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. *Psychopharmacology* (Berlin) 148(4):374-383. [Abstract Available](#)

Substance Abuse and Mental Health Services Administration, 2002. National Survey on Drug Use and Health (NSDUH), 2002. [Abstract Available](#)

Substance Abuse and Mental Health Services Administration, 2003. <http://buprenorphine.samhsa.gov>, February 12, 2003.

Tong, T.G.; Benowitz, N.L.; and Kreek, M.J., 1980. Methadone-disulfiram interaction during methadone maintenance. *Journal of Clinical Pharmacology* 20(8):506-513. [Abstract Available](#)

Uehlinger, C., et al., 1998. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *European Addiction Research* 4(Suppl 1):13-18. [Abstract Available](#)

U.S. Food and Drug Administration, 2003. Product Discontinuation Notice: ORLAAM. [www.fda.gov/cder/drug/shortages/orlaam.htm](http://www.fda.gov/cder/drug/shortages/orlaam.htm), August 23.

Varescon, I., et al., 2002. Buprenorphine abuse: High dose intravenous administration of buprenorphine [French]. *L'Encephale* 28(5 Pt. 1):397-402. [Abstract Available](#)

Vastag, B., 2003. In-office opiate treatment "not a panacea": Physicians slow to embrace therapeutic option. *Journal of the American Medical Association* 290(6):731-735. [Abstract Available](#)

Walsh, S.L., et al., 1994. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. *Clinical Pharmacology and Therapeutics* 55(5):569-580. [Abstract Available](#)

Walsh, S.L., et al., 1995. Effects of buprenorphine and methadone in methadone-maintained subjects. *Psychopharmacology* (Berlin) 119(3):268-276. [Abstract Available](#)

Wang, E.C., 1999. Methadone treatment during pregnancy. *Journal of Obstetric, Gynecologic, and Neonatal Nursing* 28(6):615-622. [Abstract Available](#)

White, J.M., and Irvine, R.J., 1999. Mechanisms of fatal opioid overdose. *Addiction* 94(7):961-972. [Abstract Available](#)

Woody, G.E., 2003. Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid-Dependent Adolescents/Young Adults. CTN protocol NIDA-CTN-0010. [www.drugabuse.gov/CTN/clinician\\_info.html](http://www.drugabuse.gov/CTN/clinician_info.html), October 31, 2003.